ORIGINAL RESEARCH PAPER

Virology

"NIPAH VIRUS: AN EMERGING ZOONOTIC THREAT AND GLOBAL PUBLIC HEALTH CHALLENGE"

KEY WORDS: Nipah virus, Emerging viruses, NiV, Paramyxovirus

Ayman Samman Respiratory Therapy, Department of Nursing, Faculty of Applied Medical Sciences, Jazan University.

ABSTRACT

Nipah virus (NiV) is a highly pathogenic virus that has emerged as a significant public health threat due to its high case fatality rates (up to 75%) and potential for causing widespread outbreaks. First identified in 1998-1999 during an outbreak among pig farmers in Malaysia and Singapore, NiV has since been associated with several outbreaks in South and Southeast Asia. This zoonotic virus, which has the potential to cause severe and often fatal disease in humans, has triggered multiple outbreaks across South and Southeast Asia, notably in Bangladesh and India. Its pathogenesis involves a complex interplay between the virus and the host's immune system, leading to severe clinical manifestations, including encephalitis and respiratory disease. Nipah virus is classified as a Biosafety Level 4 (BSL-4) pathogen due to its high fatality rate, potential for human-to-human transmission, and lack of effective treatments or vaccines. This article provides a comprehensive analysis of Nipah virus as an emerging virus, exploring its origins, transmission dynamics, clinical impact, public health implications, ongoing research, future directions in the management of Nipah virus, and the challenges it poses to global health.

Virology And Cellular Entry

Virus Structure and Genome: Nipah virus belongs to the family Paramyxoviridae and the genus Henipavirus. It is an enveloped, negative-sense, single-stranded RNA virus with a genome approximately 18.2 kb in length. The viral genome encodes six structural proteins: nucleocapsid protein (N), phosphoprotein (P), matrix protein (M), fusion protein (F), glycoprotein (G), and large polymerase protein (L) [1]. The G and F proteins play crucial roles in virus entry into host cells by mediating attachment and fusion, respectively, making them key targets for neutralizing antibodies and vaccine development [2].

Cellular Receptors: Nipah virus primarily enters host cells by binding its G glycoprotein to the ephrin-B2 and ephrin-B3 receptors on the surface of endothelial and neuronal cells. These receptors are widely expressed in human tissues, including the central nervous system (CNS) and respiratory tract, which explains the multi-organ involvement seen in NiV infections [3]. The fusion of the viral envelope with the host cell membrane is facilitated by the F protein, allowing the viral RNA to enter the cytoplasm and begin replication [4].

Viral Replication: Once inside the host cell, the NiV RNA genome is transcribed and replicated in the cytoplasm. The newly synthesized viral RNA is encapsidated by the N protein, while the P and L proteins form the RNA polymerase complex necessary for viral replication [1]. The M protein plays a role in virion assembly and budding from the host cell membrane, facilitating the release of new infectious virions [5].

Genetic Diversity: NiV exhibits considerable genetic diversity, with two main strains identified: the Malaysian strain (NiV-M) and the Bangladeshi strain (NiV-B). The NiV-B strain is associated with higher rates of human-to-human transmission and a higher case fatality rate compared to NiV-M. Genomic studies have shown that NiV-B has accumulated mutations in the F and G genes, which may contribute to its enhanced transmissibility [6].

Origins and Reservoir Hosts

Discovery of the Nipah Virus: Nipah virus was first identified in 1998-1999 following an outbreak of encephalitis and respiratory illness among pig farmers in Malaysia, which led to nearly 300 human cases over 100 deaths and the culling of over a million pigs to control the spread of the virus [7]. The virus was named after the village of Sungai Nipah, where it was first isolated. Initial investigations revealed that the virus had spilled over to pigs from fruit bats (Pteropodidae family), which are now recognized as the natural reservoir of Nipah virus [8].

The emergence of Nipah virus was linked to deforestation and habitat encroachment, which increased interactions between fruit bats, domestic animals, and humans. The infected bats likely transmitted the virus to pigs, which then served as an amplifying host, facilitating the spillover to humans. The Malaysian outbreak was unique in that pigs played a central role in the transmission cycle, a pattern not observed in subsequent outbreaks in Bangladesh and India [9].

Nipah virus (NiV) has caused multiple outbreaks since then, primarily affecting South and Southeast Asia, with Malaysia, Singapore, Bangladesh, and India being the most affected countries. In 2001, an outbreak occurred in Bangladesh, marked by a high incidence of human-to-human transmission. Subsequent outbreaks in Bangladesh and India have continued to demonstrate the virus's ability to cause severe outbreaks in densely populated areas [10]. More recently, outbreaks in the Philippines and India have highlighted the ongoing threat posed by NiV [11].

Reservoir Hosts: Fruit bats, particularly those of the genus Pteropus, are the primary natural reservoir hosts of Nipah virus. These bats are widespread across South and Southeast Asia, Australia, and parts of Africa, making the geographic range of potential Nipah virus outbreaks extensive [8]. Fruit bats harbor the virus asymptomatically, meaning they can carry and shed the virus without showing signs of illness. Nipah virus has been detected in bat urine, saliva, and feces, which can contaminate food sources or environments that humans or other animals may contact [12].

Transmission and Spillover

3.1. Zoonotic Transmission: Nipah virus is primarily a zoonotic virus. The transmission to humans typically occurs through direct contact with infected bats' secretions or excretions or through contact with infected animals, particularly pigs and horses, which can act as intermediate hosts and can then transmit the virus to humans. Another common pathway is the consumption of food products, such as date palm sap, contaminated with bat saliva or urine [13].

3.2. Spillover Events: During the 1998-1999 outbreak in Malaysia, pigs played a crucial role as intermediate hosts in the transmission of Nipah virus to humans. It is believed that fruit bats transmitted the virus to pigs, possibly through contamination of pig feed with bat saliva or urine. Once infected, pigs exhibited respiratory symptoms and encephalitis, facilitating the spread of the virus within pig farms and to human handlers [7]. The close contact between pig farmers and their livestock enabled the zoonotic transmission of the virus to humans, leading to the outbreak.

In addition to pigs, other domestic animals have been

implicated in Nipah virus transmission to humans. For example, in the Philippines, horses were identified as intermediate hosts during an outbreak in 2014. The infected horses transmitted the virus to humans, resulting in several cases of encephalitis [14]. There is also evidence of Nipah virus infection in dogs and cats, although their role in transmitting the virus to humans is less clear [15]. The potential for domestic animals to act as intermediaries highlights the importance of monitoring animal health in regions where Nipah virus is endemic.

In Bangladesh and parts of India, where raw date palm sap is a popular drink, multiple Nipah virus outbreaks have been linked to the consumption of sap contaminated by bats [16].

3.3. Human-to-Human Transmission: In contrast to the Malaysian outbreak, subsequent outbreaks, particularly in Bangladesh and India, have demonstrated significant human-to-human transmission, often within families and healthcare settings, where inadequate infection control practices are in place [17]. The exact mechanisms of human-to-human transmission are not fully understood, but transmission would likely occur through respiratory droplets, close physical contact, or exposure to bodily fluids, such as respiratory secretions, urine, or saliva, from an infected person [18].

Human-to-human transmission is a significant concern in healthcare settings, where close contact between patients and healthcare workers can facilitate the spread of the virus. The potential for sustained human-to-human transmission raises concerns about the risk of Nipah virus outbreaks in densely populated areas [19]. The NiV-B strain has shown a greater propensity for human-to-human transmission, contributing to the higher case fatality rates observed in these regions [10]. Figure 1 illustrates the primary modes of Nipah virus transmission, highlighting the most common pathways.



Figure 1 illustrates the transmission cycle of Nipah virus, showing how bats contaminate date palm sap and fruits, which then infect pigs and humans who consume these contaminated sources.

Environmental And Behavioral Risk Factors

The emergence and re-emergence of Nipah virus are influenced by various ecological, cultural, and environmental factors, including changes in land use, deforestation, climate change and agricultural practices that bring humans and domestic animals into closer contact with wildlife [20].

4.1. Deforestation and Habitat Fragmentation: Deforestation and habitat fragmentation are major environmental risk factors for Nipah virus spillover events. As forests are cleared for agriculture, urban development, or other purposes, fruit bats may roost in closer proximity to human dwellings. This increased proximity between bats and humans raises the likelihood of zoonotic transmission [21]. In Malaysia, the expansion of pig farming into forested areas may have contributed to the initial Nipah virus outbreak by bringing pigs and bats into closer contact [22].

4.2. Agricultural Practices and Livestock Management: Agricultural practices and livestock management also play a significant role in Nipah virus transmission. Intensive farming practices, particularly in regions where livestock are kept in close quarters, can facilitate the spread of the virus within animal populations and increase the risk of spillover to humans [23]. Furthermore, practices such as using bat-inhabited fruit trees to feed livestock can increase the risk of transmission from bats to animals and subsequently to humans [9]. Proper management and biosecurity measures, such as regular health monitoring of animals and the use of protective equipment by farm workers, are essential to reducing the risk of Nipah virus outbreaks in agricultural settings.

4.3. Cultural Practices and Food Consumption: Cultural practices and dietary habits can influence the risk of Nipah virus transmission. In Bangladesh and India, the consumption of raw date palm sap, which is often harvested and stored in open containers that bats can access, has been linked to several outbreaks [13]. Public health campaigns that educate communities about the risks associated with consuming raw sap and promote safer harvesting methods, such as using bamboo skirts to protect sap-collecting containers, have been effective in reducing the incidence of Nipah virus infections in these regions [24].

4.4. Climate Change and Migratory Patterns: Climate change and shifting migratory patterns of fruit bats may also impact the transmission dynamics of Nipah virus. Changes in temperature, rainfall patterns, and fruiting seasons can alter bat behavior and migration, potentially bringing bats into closer contact with human populations or new geographic areas [25]. As a result, regions that have not previously experienced Nipah virus outbreaks may become at risk, underscoring the importance of global surveillance and preparedness.

Case Studies of Zoonotic Nipah Virus Outbreaks

5.1. The Malaysian Outbreak (1998-1999):
The Malaysian outbreak is the largest recorded Nipah virus outbreak, with significant zoonotic transmission involving pigs as the intermediate host. The outbreak highlighted the role of intensive livestock farming in amplifying the virus and the importance of biosecurity measures to prevent cross-species transmission [7].

5.2. Recurrent Outbreaks in Bangladesh:
Bangladesh has experienced multiple Nipah virus outbreaks since 2001, with direct transmission from bats to humans being the primary route of infection. The consumption of raw date palm sap contaminated by bats has been a consistent risk factor. Public health interventions, such as promoting the use of bamboo skirts to protect sap-collecting jars, have been implemented to reduce this risk [19].

5.3. The Indian Outbreaks:
India has reported several Nipah virus outbreaks, with the most notable occurring in the state of Kerala in 2018. Human-to-human transmission played a significant role in the spread of the virus during this outbreak, emphasizing the need for stringent infection control measures in healthcare settings [26]. The outbreak was contained through a combination of contact tracing, quarantine, and public health education.

Clinical Manifestations

6.1. Clinical Features: Nipah virus infection typically presents with a range of symptoms, from mild flu-like illness to severe encephalitis and respiratory disease. Symptoms start mild but as the disease progresses, neurological symptoms such as altered mental status, seizures, and coma can occur, often leading to death [5]. Respiratory involvement, including

cough and difficulty breathing, is more common in NiV-B infections and is associated with a poorer prognosis [10].

6.2. Incubation Period and Initial Symptoms: Nipah virus infection in humans can range from asymptomatic to severe, with the majority of symptomatic cases presenting as acute encephalitis or respiratory illness. The incubation period for Nipah virus infection typically ranges from 4 to 14 days, but it can extend up to 45 days in some cases [5]. The initial symptoms are non-specific and resemble those of many viral infections, including fever, headache, dizziness, myalgia, vomiting, and sore throat. These early symptoms are often mild, which can lead to delays in diagnosis and treatment, especially in areas where Nipah virus is not endemic.

6.3. Neurological Manifestations: Nipah virus is highly neurotropic, and neurological symptoms often dominate the clinical picture. Patients may develop encephalitis, characterized by drowsiness, disorientation, mental confusion, and seizures. In severe cases, the encephalitis progresses rapidly to coma within 24 to 48 hours of symptom onset [27]. Magnetic resonance imaging (MRI) of the brain in affected individuals typically shows multiple small, high-intensity lesions in the subcortical and deep white matter, thalamus, and brainstem.

6.4. Respiratory Involvement: In addition to encephalitis, Nipah virus infection can lead to severe respiratory symptoms, particularly in later stages of the disease [28]. Patients may develop acute respiratory distress syndrome (ARDS), characterized by severe hypoxemia and bilateral infiltrates on chest X-ray. Respiratory involvement is more commonly observed in outbreaks in Bangladesh and India, where human-to-human transmission has been documented. This respiratory form of the disease significantly increases the risk of nosocomial transmission [29].

6.5. Gastrointestinal Symptoms: Some patients with Nipah virus infection may also experience gastrointestinal symptoms, including abdominal pain and diarrhea. These symptoms are generally less prominent than the neurological and respiratory manifestations but can contribute to the overall clinical complexity of the disease [29].

6.6. Late-Onset and Relapsing Encephalitis: Late-onset and relapsing encephalitis are recognized complications of Nipah virus infection. These conditions can occur weeks to months after the initial illness and are associated with high mortality. The pathophysiology of late-onset encephalitis is not fully understood, but it is believed to involve reactivation of the virus or an immune-mediated response [30].

6.7. Case Fatality Rate: Nipah virus is associated with a high case fatality rate, ranging from 40% to 75% depending on the outbreak and the quality of medical care available [31]. The high mortality rate is largely due to the virus's ability to cause severe encephalitis and respiratory failure. In some outbreaks, the mortality rate has exceeded 90%, particularly in settings where intensive care facilities are limited [16].

6.8. Long-Term Sequelae: Among survivors, long-term neurological sequelae are common, including persistent convulsions, personality changes, and cognitive deficits [30]. These sequelae can have a profound impact on the quality of life and underscore the need for comprehensive post-recovery care and rehabilitation for survivors.

Table 1. A Summary Of NiV Outbreaks Along With Their Associated Clinical Manifestations.

Year	Location	Cases	Deaths	CFR (%)	Key Clinical Manifestations
1998-1999	Malaysia, Singapore	283	109	38.5%	Fever, headache, encephalitis, seizures, respiratory symptoms (rare)
2001	Bangladesh	13	9	69.2%	Fever, encephalitis, altered mental status, coma
2001	India (West Bengal)	66	45	68.2%	Fever, severe encephalitis, seizures, brainstem dysfunction
2003	Bangladesh	12	8	66.7%	Fever, cough, respiratory distress, neurological symptoms
2004	Bangladesh	67	50	74.6%	Encephalitis, seizures, personality changes, coma
2005	Bangladesh	12	11	91.7%	High fever, convulsions, acute respiratory distress syndrome (ARDS)
2007	Bangladesh	8	5	62.5%	Neurological deficits, respiratory failure
2007	India (West Bengal)	5	5	100%	Severe encephalitis, seizures, coma
2008	Bangladesh	4	4	100%	Fever, altered mental status, seizures
2010	Bangladesh	16	14	87.5%	Encephalitis, cognitive impairments, coma
2011	Bangladesh	44	40	90.9%	Severe encephalitis, neurological damage, respiratory distress
2012	Bangladesh	12	10	83.3%	Fever, convulsions, brainstem dysfunction
2013	Bangladesh	24	21	87.5%	Encephalitis, personality changes, cognitive decline
2014	Bangladesh	18	9	50%	Fever, neurological complications, respiratory distress
2015	Bangladesh	9	7	77.8%	Seizures, encephalitis, respiratory failure
2018	India (Kerala)	18	17	94.4%	High fever, encephalitis, multi-organ failure
2019	India (Kerala)	1	0	0%	Isolated case, mild symptoms
2021	India (Kerala)	1	1	100%	High fever, coma, death
2023	India (Kerala)	6	2	33.3%	Fever, cough, respiratory distress, encephalitis

Pathogenesis

7.1. Overview: The pathogenesis of Nipah virus involves widespread endothelial cell infection, leading to vasculitis, thrombosis, and parenchymal necrosis in multiple organs, particularly the brain and lungs. The virus's ability to infect endothelial cells, neurons, and respiratory epithelial cells contributes to the multi-organ dysfunction observed in severe cases [5]. The G and F glycoproteins play key roles in viral entry into host cells, with the G protein binding to the cellular receptors ephrin-B2 and ephrin-B3, which are widely expressed in endothelial and neuronal tissues [3].

7.2. Early Infection and Spread: The initial sites of Nipah virus infection are typically the respiratory epithelium and endothelial cells lining blood vessels. Following inhalation or ingestion of the virus, it enters the respiratory tract and begins

replicating in the epithelial cells [32]. The virus can also infect the endothelial cells of blood vessels, leading to systemic dissemination through the bloodstream, allowing it to spread to various organs, including the brain, lungs, and kidneys. The ability of NiV to infect endothelial cells is a key factor in its pathogenesis, as it leads to widespread vasculitis, thrombosis, and hemorrhage in multiple organs [5]. This systemic spread is facilitated by the viral ability to evade the host's immune response during the early stages of infection.

7.3. Immune Evasion and Immune Response: Nipah virus employs several strategies to evade the host immune response, allowing it to establish a productive infection. The P protein of NiV can inhibit interferon (IFN) signaling by blocking the phosphorylation and activation of STAT1 and STAT2, essential components of the IFN pathway [33]. This inhibition of the IFN response prevents the host from mounting an effective antiviral defense, leading to uncontrolled viral replication and dissemination.

7.4. Pathogenesis in the Central Nervous System: One of the most severe manifestations of Nipah virus infection is encephalitis, resulting from the virus's ability to invade the central nervous system (CNS). The exact mechanisms by which NiV crosses the blood-brain barrier (BBB) are not fully understood, but it is believed that the virus can directly infect endothelial cells of the brain's vasculature, leading to increased permeability of the BBB [5]. This allows the virus to gain access to the brain parenchyma, where it infects neurons and causes widespread neuronal damage.

Once in the CNS, NiV primarily targets neurons, leading to extensive neuronal necrosis and apoptosis. The G and F proteins are crucial for viral entry into neurons, and their interaction with ephrin-B2 and ephrin-B3 receptors is thought to facilitate this process [3]. Infected neurons exhibit cytopathic effects, including syncytia formation, which contributes to the observed neurological symptoms, such as seizures, altered consciousness, and coma [5].

The infection of neurons and other CNS cells triggers a robust inflammatory response, characterized by the infiltration of immune cells such as macrophages and T cells. This inflammation exacerbates neuronal damage and contributes to the development of encephalitis [32]. Elevated levels of pro-inflammatory cytokines, including TNF- , IL-6, and IL-1 , have been detected in the cerebrospinal fluid (CSF) of patients with Nipah virus encephalitis, suggesting that a cytokine storm may play a role in the pathogenesis of severe CNS disease.

7.5. Respiratory Pathogenesis: In addition to CNS involvement, Nipah virus infection often leads to severe respiratory disease, particularly in outbreaks caused by the NiV-Bangladesh strain. The virus can infect and replicate in the epithelial cells of the respiratory tract, leading to extensive alveolar damage, pulmonary edema, and hemorrhage [34]. This pulmonary involvement is associated with a high case fatality rate, as respiratory failure is a common cause of death in NiV-infected patients.

Respiratory involvement also plays a critical role in the transmission dynamics of Nipah virus. Infected individuals can shed the virus in respiratory secretions, facilitating human-to-human transmission through close contact or exposure to respiratory droplets [18]. This mode of transmission is particularly concerning in healthcare settings, where nosocomial outbreaks have been reported [10].

7.6. Endothelial Cell Infection and Vasculopathy: Nipah virus has a strong tropism for endothelial cells, which line the blood vessels and are involved in maintaining vascular integrity. The infection of these cells by NiV leads to vasculitis, a hallmark of severe disease [35]. The binding of the viral G glycoprotein to ephrin-B2 receptors on endothelial cells triggers the fusion of the viral envelope with the cell membrane, allowing the virus to enter and replicate within these cells.

The infection of endothelial cells results in widespread vasculitis, characterized by inflammation and damage to the blood vessel walls. This can lead to thrombosis, or the formation of blood clots, which can occlude blood vessels and cause ischemic damage to various organs. Vasculitis and thrombosis contribute to the multi-organ dysfunction observed in severe cases of Nipah virus infection, including cerebral infarcts, myocardial infarctions, and renal failure [36].

In some cases, the vasculitis caused by Nipah virus infection can lead to hemorrhagic manifestations, including petechiae, ecchymoses, and gastrointestinal bleeding. This hemorrhagic syndrome is associated with a poor prognosis and is often a sign of impending multi-organ failure [32]. The underlying mechanisms involve endothelial cell damage, platelet dysfunction, and disseminated intravascular coagulation (DIC), a condition in which blood clots form throughout the body's small blood vessels.

7.7. Immune Response and Immunopathology: The innate immune response is the first line of defense against Nipah virus infection. However, the virus has evolved several mechanisms to evade this response, including the inhibition of interferon (IFN) production and signaling [33]. The P, V, and W proteins of NiV can block the activation of IFN regulatory factors (IRFs) and signal transducers and activators of transcription (STATs), preventing the expression of IFN-stimulated genes that are essential for antiviral defense.

The adaptive immune response, particularly the activation of T cells and the production of neutralizing antibodies, plays a crucial role in controlling Nipah virus infection. However, in some cases, the immune response may become dysregulated, leading to immunopathology. For example, the excessive production of pro-inflammatory cytokines and chemokines can contribute to tissue damage and exacerbate disease severity [37]. Additionally, the delayed or inadequate production of neutralizing antibodies may allow the virus to persist and cause chronic infection [38].

The immune response to Nipah virus is characterized by a robust but sometimes dysregulated response, including the production of pro-inflammatory cytokines and chemokines. Severe cases often exhibit a cytokine storm, leading to increased vascular permeability, tissue damage, and multi-organ failure [32].

Diagnostic Techniques

8.1. Laboratory Diagnosis: Accurate and timely diagnosis of Nipah virus infection is critical for patient management and outbreak control. Laboratory diagnosis primarily relies on molecular techniques, serology, and virus isolation.

RT-PCR: Reverse transcription polymerase chain reaction (RT-PCR) is the gold standard for diagnosing Nipah virus infection. RT-PCR assays targeting the N, P, and L genes of Nipah virus are highly sensitive and specific, allowing for the detection of viral RNA in various clinical samples, including blood, cerebrospinal fluid, throat swabs, and urine [7].

Serology: Enzyme-linked immunosorbent assays (ELISA) and neutralization tests are used to detect antibodies against Nipah virus in serum samples. These assays are particularly useful for retrospective diagnosis and seroprevalence studies [39].

Virus Isolation: Isolation of Nipah virus from clinical samples is possible in high-containment laboratories (BSL-4), but it is

rarely used due to the high risk associated with handling the virus [40].

8.2. Imaging and Pathology: Neuroimaging techniques such as MRI and CT scans can reveal characteristic findings in patients with Nipah virus encephalitis, including multifocal lesions in the brainstem, cerebellum, and cerebral cortex. These findings correlate with the vasculitis and parenchymal necrosis observed in histopathological studies [5].

Treatment Strategies

9.1. Supportive and Intensive Care: The cornerstone of treatment for Nipah virus infection is supportive care, aimed at managing symptoms and preventing complications. This includes maintaining hydration, managing fever, administering anticonvulsants for seizures, and ensuring respiratory support in cases of respiratory distress [27]. Given the rapid progression of the disease, early recognition and prompt supportive care are crucial to improving patient outcomes. Patients with severe encephalitis, acute respiratory distress syndrome (ARDS), or respiratory failure may require intensive care, including mechanical ventilation and intracranial pressure monitoring which are essential to prevent complications [41].

9.2. Antiviral Agents: While no specific antiviral therapy is currently approved for Nipah virus, several agents have shown potential in vitro and in animal models. However, Several antiviral agents have been tested for their efficacy against Nipah virus, with varying degrees of success. These include:

9.2.1. Ribavirin, a nucleoside analog, was one of the first antiviral agents used during Nipah virus outbreaks. It has shown some efficacy in reducing viral replication in vitro. During the Malaysian outbreak, ribavirin was administered to a small number of patients, with mixed results. Some studies suggested a reduction in mortality, while others did not find significant benefits. The use of ribavirin remains controversial due to its potential toxicity and lack of definitive evidence supporting its efficacy [42].

9.2.2. Favipiravir, an antiviral initially developed for influenza, has shown promise against Nipah virus in animal models. It works by inhibiting viral RNA polymerase, thus preventing viral replication. Studies in ferrets have demonstrated that favipiravir can reduce viral load and improve survival rates when administered early in the course of infection. However, clinical trials in humans are needed to confirm its efficacy and safety for treating Nipah virus [43].

9.2.3. Remdesivir, an antiviral that gained prominence during the COVID-19 pandemic, has also been tested against Nipah virus. In vitro studies have shown that remdesivir can inhibit Nipah virus replication. Animal studies have demonstrated its potential to reduce viral load and improve survival, particularly when administered early in the infection. However, like favipiravir, remdesivir has yet to undergo clinical trials for Nipah virus specifically [44].

9.2.4. Monoclonal antibodies targeting the Nipah virus glycoproteins (G and F) have shown promise in preclinical studies. These antibodies can neutralize the virus and prevent it from entering host cells. One such antibody, m102.4, has been tested in animal models and shown to provide protection against lethal Nipah virus challenge. While m102.4 has been used on a compassionate basis during outbreaks, large-scale clinical trials are needed to establish its efficacy and safety [38].

9.2.5. Small interfering RNAs (siRNAs) are another experimental approach being explored for Nipah virus treatment. siRNAs can specifically target and degrade viral RNA, inhibiting viral replication. Preclinical studies using siRNAs targeting Nipah virus genes have shown promising results in reducing viral load and improving survival in animal models. However, challenges such as delivery methods and potential off-target effects need to be addressed before siRNAs can be considered a viable treatment option [45].

9.3. Immunotherapy: Monoclonal antibodies targeting the Nipah virus G glycoprotein, such as m102.4, have shown efficacy in animal models and have been used on a compassionate basis in some outbreaks. These antibodies neutralize the virus by preventing it from binding to host cell receptors, thus blocking viral entry [38]. However, large-scale clinical trials are necessary to establish their safety and effectiveness in humans.

Passive immunotherapy involves the administration of antibodies from recovered patients or animals to provide immediate, although temporary, protection against infection. Convalescent plasma therapy, which uses plasma from recovered patients, has been considered for treating Nipah virus infection. While this approach has been successful in other viral infections, such as Ebola, its efficacy against Nipah virus has not been conclusively demonstrated. Further studies are needed to assess the potential benefits and risks of passive immunotherapy in Nipah virus outbreaks [38].

9.4. Vaccine Development: Developing a vaccine for Nipah virus has been a high priority for researchers. Several vaccine candidates are in various stages of development, including recombinant protein vaccines, vector-based vaccines, and nucleic acid-based vaccines.

9.4.1. Recombinant Protein Vaccines: These vaccines use purified viral proteins to elicit an immune response. A vaccine based on the Nipah virus G glycoprotein has shown promise in animal models, providing protection against lethal challenge. This approach is being further developed for potential use in humans [46].

9.4.2. Vector-Based Vaccines: Vector-based vaccines use harmless viruses to deliver Nipah virus genes into the host cells, prompting an immune response. A vaccine using a recombinant vesicular stomatitis virus (rVSV) expressing the Nipah virus G protein has been shown to protect animals against Nipah virus infection. This platform was also used successfully in the development of the Ebola vaccine, making it a promising candidate for Nipah virus [47].

9.4.3. Nucleic Acid-Based Vaccines: Nucleic acid-based vaccines, such as mRNA vaccines, have gained attention due to their success in the COVID-19 pandemic. Researchers are exploring the use of mRNA vaccines encoding Nipah virus proteins to induce an immune response. Early studies in animal models have shown that these vaccines can generate strong immune responses, but more research is needed to determine their efficacy and safety in humans [48].

Public Health Implications and Prevention Strategies

10.1. Surveillance and Early Detection: Surveillance is critical for the early detection and management of Nipah virus outbreaks. Monitoring bat populations, domestic animals, and human cases in regions at risk of Nipah virus spillover can help identify potential outbreaks before they spread widely [9]. Surveillance efforts should include serological testing, virus isolation, and genetic sequencing to track the emergence and spread of different Nipah virus strains [1]. Additionally, integrating One Health approaches that consider the interconnectedness of human, animal, and environmental health is essential for effective surveillance and response.

10.2. Infection Control and Biosecurity: Such measures are crucial for preventing Nipah virus transmission in healthcare settings, farms, and communities. Healthcare workers should

be trained to recognize Nipah virus symptoms and implement strict infection control protocols, including the use of personal protective equipment (PPE), isolation of infected patients, and proper disinfection of medical equipment and surfaces [27]. On farms, biosecurity measures such as controlling animal movement, ensuring clean water and feed, and minimizing contact between livestock and wild animals can reduce the risk of Nipah virus introduction and spread.

10.3. Public Health Education and Community Engagement: This is a key component of Nipah virus prevention. Educating communities about the risks associated with bat exposure, the dangers of consuming raw date palm sap, and the importance of hygiene and infection control measures can reduce the risk of transmission [16]. Public health campaigns should be culturally sensitive and tailored to the specific practices and beliefs of at-risk populations [13]. Engaging local leaders, healthcare workers, and community members in these efforts can enhance their effectiveness and sustainability.

10.4. Infection Control in Healthcare Settings: Strict infection control measures are essential to prevent human-to-human transmission of Nipah virus in healthcare settings. This includes the use of personal protective equipment (PPE), isolation of infected patients, and proper disinfection of medical equipment and surfaces. Healthcare workers should be trained in the recognition of Nipah virus symptoms and the implementation of appropriate infection control protocols.

10.5. Vaccine Development: Although there is currently no licensed vaccine for Nipah virus, research is ongoing to develop effective vaccines. Several vaccine candidates are in various stages of development, including recombinant vesicular stomatitis virus (rVSV)-based vaccines and subunit vaccines. The development and deployment of an effective Nipah virus vaccine would be a major breakthrough in preventing future outbreaks [49].

10.6. Wildlife Conservation and Habitat Protection: Protecting wildlife habitats and conserving biodiversity can help mitigate the risk of Nipah virus spillover by reducing the likelihood of bat-human interactions. Conservation efforts should focus on preserving natural habitats for fruit bats and other wildlife, preventing deforestation and land conversion, and promoting sustainable land-use practices [50]. Additionally, establishing protected areas and wildlife corridors can help maintain healthy bat populations and reduce the need for bats to seek food and shelter in human-dominated landscapes.

10.7. International Collaboration: Given the transboundary nature of Nipah virus, international collaboration is essential for effective prevention and control. This includes sharing of information and resources between affected countries, coordination of research efforts, and joint responses to outbreaks. Global health organizations such as the World Health Organization (WHO) play a key role in facilitating these collaborations and ensuring a coordinated response to Nipah virus outbreaks [10].

Challenges and Future Directions

11.1. Lack of Specific Treatments and Vaccines: One of the most significant challenges in combating Nipah virus is the absence of specific antiviral treatments or vaccines. Current management of Nipah virus infection is limited to supportive care, with no approved drugs specifically targeting the virus [42]. While experimental therapies such as ribavirin, monoclonal antibodies, and antiviral agents like favipiravir and remdesivir are being explored, their efficacy in humans remains unproven [51].

Vaccine development efforts are ongoing, with several candidates showing promise in preclinical studies, including recombinant protein vaccines and vector-based vaccines. However, the sporadic nature of Nipah outbreaks and the logistical challenges of conducting clinical trials in affected regions have slowed progress.

11.2. Diagnostic Challenges: Early diagnosis of Nipah virus infection is challenging due to the non-specific nature of initial symptoms, which can be easily mistaken for other febrile illnesses. Laboratory confirmation requires specialized facilities equipped with BSL-4 containment, which are not widely available, particularly in low-resource settings [41]. Point-of-care diagnostic tools are urgently needed to enable rapid identification of Nipah virus cases, especially in remote or outbreak-prone areas. Enhanced diagnostic tools would also facilitate more effective surveillance and outbreak response [1].

11.3. Economic and Social Impact: Socioeconomic factors, such as poverty, lack of access to healthcare, and reliance on traditional practices, can exacerbate the impact of Nipah virus outbreaks. Addressing these underlying factors is crucial for reducing the vulnerability of affected populations and improving the overall resilience to zoonotic diseases. This includes investing in healthcare infrastructure, promoting economic development, and ensuring equitable access to healthcare services [52].

Nipah virus outbreaks have significant economic and social impacts, particularly in affected regions. The 1999 outbreak in Malaysia, for example, led to the culling of over a million pigs, devastating the country's pig farming industry and resulting in significant economic losses [7]. The social impact of outbreaks is also profound, with communities experiencing stigma, fear, and disruption to daily life due to quarantine measures and the loss of loved ones.

11.4. Risk of Global Spread: While Nipah virus has primarily affected South and Southeast Asia, the risk of global spread cannot be ignored. Increased global travel and trade, coupled with the potential for human-to-human transmission, raise concerns about the virus's ability to cause outbreaks in new regions [53]. The emergence of other zoonotic viruses, such as SARS-CoV-2, has highlighted the need for global preparedness to prevent and respond to potential pandemics.

11.5. Limited Outbreak Data: One of the major challenges in developing treatments for Nipah virus is the relatively small number of cases and outbreaks, which limits the availability of clinical data. This scarcity of data makes it difficult to conduct large-scale clinical trials to test the efficacy of potential treatments. Additionally, the sporadic nature of Nipah virus outbreaks complicates efforts to study the virus in the field [19].

11.6. Biosafety Concerns: Nipah virus is classified as a Biosafety Level 4 (BSL-4) pathogen, meaning that research on the virus must be conducted in highly secure laboratories. The stringent biosafety requirements limit the number of facilities that can conduct research on Nipah virus, slowing the progress of treatment and vaccine development. Moreover, the high fatality rate of the virus poses ethical and logistical challenges in conducting clinical trials [53].

11.7. Ethical Considerations: The ethical challenges of conducting clinical trials during outbreaks cannot be overlooked. During outbreaks, the urgency to find effective treatments often leads to the use of experimental therapies under compassionate use protocols. However, this can complicate the interpretation of treatment efficacy and safety data. Balancing the need for rapid treatment development with ethical considerations remains a significant challenge in the field [54].

11.8. Funding and Resources: Securing adequate funding and

resources for Nipah virus research has been a persistent challenge. Given the sporadic nature of outbreaks and the relatively low global incidence, Nipah virus has not attracted the same level of funding as other infectious diseases like influenza or HIV. This lack of funding hampers the development of treatments and vaccines, as well as the ability to conduct large-scale clinical trials [55].

12. 5. Future Directions in Nipah Virus Research, Treatment and Control

12.1. Strengthening Surveillance and Early Warning Systems: Improving surveillance systems in regions at risk of Nipah virus outbreaks is crucial for early detection and rapid response. This allows for the timely administration of experimental therapies and containment measures. Integrating wildlife surveillance, particularly in bat populations, with human health monitoring can help identify potential spillover events before they lead to large-scale outbreaks [12]. Integrating modern diagnostic tools, such as point-of-care tests and molecular assays, into surveillance programs will enhance the ability to quickly identify and respond to Nipah virus cases [41].

12.2. Advancing Vaccine and Therapeutic Development: Continued investment in vaccine and therapeutic development is essential to reduce the impact of future Nipah virus outbreaks. Future research should focus on advancing antiviral candidates that have shown promise in preclinical studies, such as favipiravir, remdesivir, and monoclonal antibodies. Conducting clinical trials in regions at risk of Nipah virus outbreaks will be crucial to determine the efficacy and safety of these treatments. Collaborative efforts between governments, international organizations, and pharmaceutical companies can accelerate the development and distribution of vaccines and antiviral treatments [44]. Given the success of mRNA vaccines in the COVID-19 pandemic, similar platforms could be explored for Nipah virus, potentially shortening the timeline for vaccine availability [56].

12.3. Enhancing Public Health Infrastructure: Strengthening healthcare infrastructure in at-risk regions is critical to improving outbreak response and patient outcomes. This includes ensuring that healthcare facilities are equipped with the necessary resources, such as intensive care units, mechanical ventilators, personal protective equipment, and trained healthcare workers, to manage Nipah virus cases effectively. Capacity building through training and education can also enhance the ability of healthcare systems to respond to outbreaks. Training healthcare workers to recognize and manage Nipah virus cases is also critical to reducing mortality [57].

12.4. Promoting One Health Approaches: The emergence of Nipah virus highlights the need for a One Health approach that recognizes the interconnectedness of human, animal, and environmental health. Addressing the drivers of Nipah virus emergence, such as deforestation and wildlife habitat disruption, requires coordinated efforts across multiple sectors, including agriculture, wildlife conservation, and public health. Collaborative research and policy initiatives can help mitigate the risk of future zoonotic spillovers.

12.5. International Collaboration and Preparedness: International collaboration is key to addressing the global threat posed by Nipah virus. Sharing data, research findings, and resources between countries can enhance preparedness and response efforts. The World Health Organization (WHO) and other global health organizations play a crucial role in coordinating these efforts and ensuring that low-resource countries have access to the tools and knowledge needed to combat Nipah virus.

CONCLUSION

Nipah virus remains a formidable public health threat due to its high case fatality rate, potential for human-to-human transmission, and lack of effective treatment or vaccines. Its emergence is closely linked to ecological disruptions, such as deforestation and wildlife encroachment, which facilitate spillover events from bats to humans. The virus's ability to cause severe encephalitis and respiratory disease underscores the urgent need for improved surveillance, rapid diagnostics, and effective therapeutic interventions. Past outbreaks, particularly in Malaysia, Bangladesh, and India, have highlighted the varied transmission dynamics and the necessity for region-specific prevention strategies, including strict biosecurity measures in livestock farming, enhanced infection control in healthcare settings, and public education to reduce exposure risks.

Looking ahead, a multifaceted approach combining scientific research, global cooperation, and community engagement is crucial in mitigating future outbreaks. Advancements in vaccine development, including mRNA and vector-based platforms, show promise in offering long-term protection. Strengthening public health infrastructure, integrating One Health principles, and fostering international collaborations will be vital in preventing and managing future outbreaks. With proactive measures, including early detection, effective response strategies, and sustained research efforts, the global community can work toward reducing the burden of Nipah virus and preventing it from evolving into a larger pandemic threat.

REFERENCES:

[1] B. H. Harcourt et al., "Molecular Characterization of Nipah Virus, a Newly Emergent Paramyxovirus," Virology, vol. 271, no. 2, pp. 334–349, Jun. 2000, doi: 10.1006/viro.2000.0340.

[2] C. C. Broder et al., "A treatment for and vaccine against the deadly Hendra and Nipah viruses," Antiviral Res., vol. 100, no. 1, pp. 8–13, Oct. 2013, doi: 10.1016/j.antiviral.2013.06.012.

[3] M. I. Bonaparte et al., "Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus," Proc. Natl. Acad. Sci. U. S. A., vol. 102, no. 30, pp. 10652–10657, Jul. 2005, doi: 10.1073/pnas.0504887102.

[4] L. Priyadarsinee, H. Sarma, and G. N. Sastry, "Glycoprotein attachment with host cell surface receptor ephrin B2 and B3 in mediating entry of nipah and hendra virus: a computational investigation," J. Chem. Sci. Bangalore India, vol. 134, no. 4, p. 114, 2022, doi: 10.1007/s12039-022-02110-9.

[5] K. T. Wong and C. T. Tan, "Clinical and pathological manifestations of human henipavirus infection," Curr. Top. Microbiol. Immunol., vol. 359, pp. 95–104, 2012, doi: 10.1007/82_2012_205.

[6] V. A. Arankalle et al., "Genomic characterization of Nipah virus, West Bengal, India," Emerg. Infect. Dis., vol. 17, no. 5, pp. 907–909, May 2011, doi: 10.3201/eid1705.100968.

[7] K. B. Chua et al., "Nipah virus: a recently emergent deadly paramyxovirus," Science, vol. 288, no. 5470, pp. 1432–1435, May 2000, doi: 10.1126/science.288.5470.1432.

[8] J. M. Yob et al., "Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia," Emerg. Infect. Dis., vol. 7, no. 3, pp. 439–441, 2001, doi: 10.3201/eid0703.010312.

[9] H. Field, P. Young, J. M. Yob, J. Mills, L. Hall, and J. Mackenzie, "The natural history of Hendra and Nipah viruses," Microbes Infect., vol. 3, no. 4, pp. 307–314, Apr. 2001, doi: 10.1016/s1286-4579(01)01384-3.

[10] V. P. Hsu et al., "Nipah virus encephalitis reemergence, Bangladesh," Emerg. Infect. Dis., vol. 10, no. 12, pp. 2082–2087, Dec. 2004, doi: 10.3201/eid1012.040701.

[11] G. Arunkumar et al., "Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018," J. Infect. Dis., vol. 219, no. 12, pp. 1867–1878, May 2019, doi: 10.1093/infdis/jiy612.

[12] J. H. Epstein et al., "Pteropus vampyrus , a hunted migratory species with a multinational home-range and a need for regional management," J. Appl. Ecol., vol. 46, no. 5, pp. 991–1002, Oct. 2009, doi: 10.1111/j.1365-2664.2009.01699.x.

[13] M. A. Rahman et al., "Date palm sap linked to Nipah virus outbreak in Bangladesh, 2008," Vector Borne Zoonotic Dis. Larchmt. N, vol. 12, no. 1, pp. 65–72, Jan. 2012, doi: 10.1089/vbz.2011.0656.

[14] S. Weatherman, H. Feldmann, and E. de Wit, "Transmission of henipaviruses," Curr. Opin. Virol., vol. 28, pp. 7–11, Feb. 2018, doi: 10.1016/j.coviro.2017.09.004.

[15] L. Bruno et al., "Nipah Virus Disease: Epidemiological, Clinical, Diagnostic and Legislative Aspects of This Unpredictable Emerging Zoonosis," Anim. Open Access J. MDPI, vol. 13, no. 1, p. 159, Dec. 2022, doi: 10.3390/ani13010159.

[16] S. P. Luby et al., "Recurrent zoonotic transmission of Nipah virus into humans, Bangladesh, 2001-2007," Emerg. Infect. Dis., vol. 15, no. 8, pp. 1229–1235, Aug. 2009, doi: 10.3201/eid1508.081237.

[17] S. P. Luby et al., "Foodborne transmission of Nipah virus, Bangladesh," Emerg. Infect. Dis., vol. 12, no. 12, pp. 1888–1894, Dec. 2006, doi: 10.3201/eid1212.060732.

[18] E. S. Gurley et al., "Person-to-person transmission of Nipah virus in a Bangladeshi community," Emerg. Infect. Dis., vol. 13, no. 7, pp. 1031–1037, Jul. 2007, doi: 10.3201/eid1307.061128.

[19] E. S. Gurley et al., "Convergence of Humans, Bats, Trees, and Culture in Nipah Virus Transmission, Bangladesh," Emerg. Infect. Dis., vol. 23, no. 9, pp.

1446–1453, Sep. 2017, doi: 10.3201/eid2309.161922.
[20] P. Daszak, A. A. Cunningham, and A. D. Hyatt, "Emerging infectious diseases of wildlife--threats to biodiversity and human health," Science, vol. 287, no. 5452, pp. 443–449, Jan. 2000, doi: 10.1126/science.287.5452.443.
[21] R. K. Plowright et al., "Land use-induced spillover: a call to action to safeguard environmental, animal, and human health," Lancet Planet. Health, vol. 5, no. 4, pp. e237–e245, Apr. 2021, doi: 10.1016/S2542-5196(21)00031-0.
[22] J. R. C. Pulliam et al., "Agricultural intensification, priming for persistence and the emergence of Nipah virus: a lethal bat-borne zoonosis," J. R. Soc. Interface, vol. 9, no. 66, pp. 89–101, Jan. 2012, doi: 10.1098/rsif.2011.0223.
[23] M. N. Mohd Nor, C. H. Gan, and B. L. Ong, "Nipah virus infection of pigs in peninsular Malaysia," Rev. Sci. Tech. Int. Off. Epizoot., vol. 19, no. 1, pp. 160–165, Apr. 2000, doi: 10.20506/rst.19.1.1202.
[24] N. Nahar, R. Sultana, E. S. Gurley, M. J. Hossain, and S. P. Luby, "Date palm sap collection: exploring opportunities to prevent Nipah transmission," EcoHealth, vol. 7, no. 2, pp. 196–203, Jun. 2010, doi: 10.1007/s10393-010-0320-3.
[25] A. D. Luis et al., "A comparison of bats and rodents as reservoirs of zoonotic viruses: are bats special?," Proc. Biol. Sci., vol. 280, no. 1756, p. 20122753, Apr. 2013, doi: 10.1098/rspb.2012.2753.
[26] G. Arunkumar et al., "Outbreak Investigation of Nipah Virus Disease in Kerala, India, 2018," J. Infect. Dis., vol. 219, no. 12, pp. 1867–1878, May 2019, doi: 10.1093/infdis/jiy612.
[27] K. J. Goh et al., "Clinical features of Nipah virus encephalitis among pig farmers in Malaysia," N. Engl. J. Med., vol. 342, no. 17, pp. 1229–1235, Apr. 2000, doi: 10.1056/NEJM200004273421701.
[28] B. Thomas et al., "Nipah Virus Infection in Kozhikode, Kerala, South India, in 2018: Epidemiology of an Outbreak of an Emerging Disease," Indian J. Community Med. Off. Publ. Indian Assoc. Prev. Soc. Med., vol. 44, no. 4, pp. 383–387, 2019, doi: 10.4103/ijcm.IJCM_198_19.
[29] M. J. Hossain et al., "Clinical Presentation of Nipah Virus Infection in Bangladesh," Clin. Infect. Dis., vol. 46, no. 7, pp. 977–984, Apr. 2008, doi: 10.1086/529147.
[30] C. T. Tan et al., "Relapsed and late-onset Nipah encephalitis," Ann. Neurol., vol. 51, no. 6, pp. 703–708, Jun. 2002, doi: 10.1002/ana.10212.
[31] M. S. Chadha et al., "Nipah virus-associated encephalitis outbreak, Siliguri, India," Emerg. Infect. Dis., vol. 12, no. 2, pp. 235–240, Feb. 2006, doi: 10.3201/eid1202.051247.
[32] B. Rockx et al., "A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment," J. Virol., vol. 84, no. 19, pp. 9831–9839, Oct. 2010, doi: 10.1128/JVI.01163-10.
[33] M. L. Shaw, A. García-Sastre, P. Palese, and C. F. Basler, "Nipah Virus V and W Proteins Have a Common STAT1-Binding Domain yet Inhibit STAT1 Activation from the Cytoplasmic and Nuclear Compartments, Respectively," J. Virol., vol. 78, no. 11, pp. 5633–5641, Jun. 2004, doi: 10.1128/JVI.78.11.5633-5641.2004.
[34] O. Escaffre, V. Borisevich, L. A. Vergara, J. W. Wen, D. Long, and B. Rockx, "Characterization of Nipah virus infection in a model of human airway epithelial cells cultured at an air-liquid interface," J. Gen. Virol., vol. 97, no. 5, pp. 1077–1086, May 2016, doi: 10.1099/jgv.0.000441.
[35] C. Mathieu and B. Horvat, "Henipavirus pathogenesis and antiviral approaches," Expert Rev. Anti Infect. Ther., vol. 13, no. 3, pp. 343–354, Mar. 2015, doi: 10.1586/14787210.2015.1001838.
[36] K. T. Wong et al., "Human Hendra virus infection causes acute and relapsing encephalitis," Neuropathol. Appl. Neurobiol., vol. 35, no. 3, pp. 296–305, Jun. 2009, doi: 10.1111/j.1365-2990.2008.00991.x.
[37] J. M. Criglar et al., "A Novel Form of Rotavirus NSP2 and Phosphorylation-Dependent NSP2-NSP5 Interactions Are Associated with Viroplasm Assembly," J. Virol., vol. 88, no. 2, pp. 786–798, Jan. 2014, doi: 10.1128/JVI.03022-13.
[38] K. N. Bossart et al., "A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection," PLoS Pathog., vol. 5, no. 10, p. e1000642, Oct. 2009, doi: 10.1371/journal.ppat.1000642.
[39] P. Lawrence and B. Escudero-Pérez, "Henipavirus Immune Evasion and Pathogenesis Mechanisms: Lessons Learnt from Natural Infection and Animal Models," Viruses, vol. 14, no. 5, p. 936, Apr. 2022, doi: 10.3390/v14050936.
[40] P. Daniels, T. Ksiazek, and B. T. Eaton, "Laboratory diagnosis of Nipahand Hendra virus infections," Microbes Infect., vol. 3, no. 4, pp. 289–295, Apr. 2001, doi: 10.1016/S1286-4579(01)01382-X.
[41] B. S. P. Ang, T. C. C. Lim, and L. Wang, "Nipah Virus Infection," J. Clin. Microbiol., vol. 56, no. 6, pp. e01875-17, Jun. 2018, doi: 10.1128/JCM.01875-17.
[42] H. T. Chong et al., "Treatment of acute Nipah encephalitis with ribavirin," Ann. Neurol., vol. 49, no. 6, pp. 810–813, Jun. 2001, doi: 10.1002/ana.1062.
[43] B. E. Dawes et al., "Favipiravir (T-705) protects against Nipah virus infection in the hamster model," Sci. Rep., vol. 8, no. 1, p. 7604, May 2018, doi: 10.1038/s41598-018-25780-3.
[44] M. K. Lo et al., "Remdesivir (GS-5734) protects African green monkeys from Nipah virus challenge," Sci. Transl. Med., vol. 11, no. 494, p. eaau9242, May 2019, doi: 10.1126/scitranslmed.aau9242.
[45] A. K. Gupta et al., "NipahVR: a resource of multi-targeted putative therapeutics and epitopes for the Nipah virus," Database, vol. 2020, p. baz159, Jan. 2020, doi: 10.1093/database/baz159.
[46] J. A. Pallister et al., "Vaccination of ferrets with a recombinant G glycoprotein subunit vaccine provides protection against Nipah virus disease for over 12 months," Virol. J., vol. 10, p. 237, Jul. 2013, doi: 10.1186/1743-422X-10-237.
[47] S. L. Foster et al., "A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease," Proc. Natl. Acad. Sci., vol. 119, no. 12, p. e2200065119, Mar. 2022, doi: 10.1073/pnas.2200065119.
[48] M. Fatima, P.-G. Park, and K.-J. Hong, "Clinical advancements in mRNA vaccines against viral infections," Clin. Immunol. Orlando Fla, vol. 271, p. 110424, Feb. 2025, doi: 10.1016/j.clim.2024.110424.
[49] T. P. Monath et al., "Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential," PLoS Pathog., vol. 18, no. 6, p. e1010658, Jun. 2022, doi: 10.1371/journal.ppat.1010658.
[50] K. J. Olival and P. Daszak, "The ecology of emerging neurotropic viruses," J. Neurovirol., vol. 11, no. 5, pp. 441–446, Oct. 2005, doi: 10.1080/13550280591002450.
[51] G. Mishra, V. Prajapat, and D. Nayak, "Advancements in Nipah virus treatment: Analysis of current progress in vaccines, antivirals, and therapeutics," Immunology, vol. 171, no. 2, pp. 155–169, Feb. 2024, doi: 10.1111/imm.13695.
[52] R. A. Weiss and A. J. McMichael, "Social and environmental risk factors in the emergence of infectious diseases," Nat. Med., vol. 10, no. 12 Suppl, pp. S70-76, Dec. 2004, doi: 10.1038/nm1150.
[53] M. K. Lo and P. A. Rota, "The emergence of Nipah virus, a highly pathogenic paramyxovirus," J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol., vol. 43, no. 4, pp. 396–400, Dec. 2008, doi: 10.1016/j.jcv.2008.08.007.
[54] T. Johnson, E. Jamrozik, T. Hurst, P. Y. Cheah, and M. J. Parker, "Ethical issues in Nipah virus control and research: addressing a neglected disease," J. Med. Ethics, vol. 50, no. 9, pp. 612–617, Aug. 2024, doi: 10.1136/jme-2023-109469.
[55] R. K. Singh et al., "Nipah virus: epidemiology, pathology, immunobiology and advances in diagnosis, vaccine designing and control strategies - a comprehensive review," Vet. Q., vol. 39, no. 1, pp. 26–55, Dec. 2019, doi: 10.1080/01652176.2019.1580827.
[56] P. Mohapatra et al., "Addressing the Nipah virus threat: A call for global vigilance and coordinated action," Clin. Infect. Pract., vol. 24, p. 100390, Nov. 2024, doi: 10.1016/j.clinpr.2024.100390.
[57] R. R. Sahay et al., "Experiential learnings from the Nipah virus outbreaks in Kerala towards containment of infectious public health emergencies in India," Epidemiol. Infect., vol. 148, p. e90, Apr. 2020, doi: 10.1017/S0950268820000825.